vimarsana.com


Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion's ML-enabled Operating System for the potential treatment of C. difficile.

Related Keywords

Chris Gibson ,Elyse Freeman ,Exchange Commission ,Recursion Pharmaceuticals Inc ,Nasdaq ,Recursion Pharmaceuticals ,New Chemical Entity ,Recursion Operating System ,Operating System ,Recursion Map ,Securities Litigation Reform Act ,கிறிஸ் கிப்சன் ,பரிமாற்றம் தரகு ,நாஸ்டாக் ,புதியது இரசாயன நிறுவனம் ,இயங்குகிறது அமைப்பு ,பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.